Neutralizing antibody responses in recent seroconverters with HIV-1 subtype C infections in India

AIDS Research and Human Retroviruses

Volumn 24, Issue 9, 2008, Pages 1159-1166

  Kulkarni, Smita ^a,c   Tripathy, Srikanth ^a   Gangakhedkar, Raman ^a   Jadhav, Sushama ^a   Agnihotri, Kalpana ^a   Sane, Suvarna ^a   Bollinger, Robert ^b   Paranjape, Ramesh ^a  

^a NATIONAL AIDS RESEARCH INSTITUTE   (India)

^b JOHNS HOPKINS UNIVERSITY   (United States)

^c Maharashtra Industrial Development Corporation India   (India)

Author keywords

[No Author keywords available]

Indexed keywords

HUMAN IMMUNODEFICIENCY VIRUS VACCINE; NEUTRALIZING ANTIBODY;

ADOLESCENT; ADULT; ANTIBODY RESPONSE; ARTICLE; CD4 LYMPHOCYTE COUNT; CLINICAL ARTICLE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FOLLOW UP; GENE MUTATION; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INDIA; MALE; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA SEQUENCE; SEROCONVERSION; SERODIAGNOSIS; VIRUS LOAD; VIRUS NEUTRALIZATION;

AMINO ACID SEQUENCE; CD4 LYMPHOCYTE COUNT; ENV GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; GENOTYPE; HIV ANTIBODIES; HIV INFECTIONS; HIV-1; HUMANS; INDIA; LONGITUDINAL STUDIES; MOLECULAR SEQUENCE DATA; NEUTRALIZATION TESTS; SEQUENCE ANALYSIS, DNA; TIME FACTORS; VIRAL LOAD;

EID: 51849146675     PISSN: 08892229     EISSN: None     Source Type: Journal    
DOI: 10.1089/aid.2007.0296     Document Type: Article

References (35)

1. Arther LO, Bess JW Jr, Waters DJ, Pyle SW, Kelliher JC, Nara PL, et al.: Challenge of chimpanzees (Pan troglodytes) immunized with human immunodeficiency virus envelope glycoprotein gp120. J Virol 1989;63:5046-5053.
2. Berman PW, Gregory TJ, Riddle L, Nakamura GR, Champe MA, Porter JP, et al.: Protection of chimpanzee from infection by HIV-1 after vaccination with recombinant glycoprotein gp120 but not with gp160. Nature 1990;345:622-625.
3. Ferrantelli F, Rasmussen RA, Buckley KA, Li PL, Xu W, Wang T, et al.: Complete protection of neonatal macaques against oral challenge with pathogenic SHIV by human anti-HIV monoclonal antibodies. J Infect Dis 2004;189:2167-2173.
4. Mascola JR, Stiegler G, VanCott TC, Katinger H, Carpenter CB, Hanson CE, et al.: Protection of macaques against vaginal transmission of a pathogenic HIV-1/SIV chimeric virus by passive infusion of neutralizing antibodies. Nat Med 2000;6:207-210.
5. Gilbert PB, Peterson ML, Follmann D, Hudgens MG, Francis DP, Gurwith M, et al.: Correlation between immunologic responses to a recombinant glycoprotein 120 vaccine and incidence of HIV-1 infection in a phase 3 HIV-1 preventive vaccine trial. J Infect Dis 2005;191:666-677.
6. Lyles RH, Munoz, A, Yamashita TE, Bazmi H, Detels R, Rinaldo CR, et al.: Natural history of human immunodeficiency virus type 1 viremia after seroconversion and proximal to AIDS in a large cohort of homosexual men. Multicenter AIDS Cohort Study. J Infect Dis 2000;181:872-880.
7. Lathey JL, Pratt RD, and Spector SA: Appearance of autologous neutralizing antibody correlates with reduction in viral load and phenotypic switch during primary infection with human immunodeficiency virus type-1. J Infect Dis 1997;175:231-232.
8. Moog C, Fleury HJA, Pellegrin I, Kirn A, and Aubertin AM: Autologous and heterologous neutralizing antibody responses following initial seroconversion in human immunodeficiency virus type-1-infected individuals. J Virol 1997;71:3734-3741.
9. Montefiori DC, Altfeld M, Lee PK, Bilska M, Zhou J, Johnston MN, et al.: Viremia control despite escape from a rapid and potent autologous neutralizing antibody response after therapy cessation in an HIV-1-infected individual. J Immunol 2003;170:3906-3914.
10. Pellegrin I, Legrand E, Neau D, Bonot P, Masquelier B, Pellegrin J, et al.: Kinetics of appearance of neutralizing antibodies in 12 patients with primary or recent HIV-1 infection and relationship with plasma and cellular viral loads. J Acquir Immune Defic Syndr Hum Retroviral 1996;11:438-447.
11. Ruppach H, Nara P, Raudonat I, Elanjikal Z, Rubsamen-Waigmann, H, and Dietrich U: Human immunodeficiency virus (HIV)-positive sera obtained shortly after seroconversion neutralizes autologous HIV type 1 isolates on primary macrophages but not on lymphocytes. J Virol 2000;74:5403-5411.
12. Wei X, Decker JM, Wang S, Hui H, Kappes JC, Wu X, et al.: Antibody neutralization and escape by HIV-1. Nature 2003;422:307-312.
13. Zwart G, Back NKT, Ramautarsingh C, Valk M, Van der Hock L, and Goudsmit J: Frequent and early HIV-1 MN neutralizing capacity in sera from Dutch HIV-1 seroconverters is related to antibody reactivity to peptides from the gp 120 V3 domain. AIDS Res Hum Retroviruses 1994;10:245-250.
14. Gadkari DA, Moore D, Sheppard HW, Kulkarni SS, Mehendale SM, and Bollinger RC: Transmission of genetically diverse strains of HIV-1 in Pune, India. Indian J Med Res 1998;107:1-9.
15. Jameel S, Zaffrullah M, Ahmad M, Kapoor GS, and Sehgal S: A genetic analysis of HIV-1 from Punjab, India reveals the presence of multiple variants. AIDS 1995;9:685-690.
16. Agnihotri K, Tripathy S, Jere A, Jadhav S, Kurle S, and Paranjape R: gp120 sequences from HIV type 1 subtype C early seroconverters in India. AIDS Res Hum Retroviruses 2004;20:889-894.
17. Shankarappa R, Chatterjee R, Learn GH, Neogi D, Ding M, Roy P, Ghosh A, Kingsley L, Harrison L, Mullins JI, and Gupta P: Human immunodeficiency virus type 1 env sequences from Calcutta in eastern India: Identification of features that distinguish subtype C sequences in India from other subtype C sequences. J Virol 2001;75:10479-10487.
18. Thakar MR, Bhonge LS, Lakhashe SK, Shankarkumar U, Sane SS, Kulkarni SS, Mahajan BA, and Paranjape RS: Cytolytic T lymphocytes (CTLs) from HIV-1 subtype C-infected Indian patients recognize CTL epitopes from a conserved immunodominant region of HIV-1 Gag and Nef. J Infect Dis 2005;192:749-759.
19. da Silva J: The evolutionary adaptation of HIV-1 to specific immunity. Curr HIV Res 2002;1:363-371.
20. Cecilia D, Kewalramani, VN, O'Leary J, Volsky B, Nyambi P, Burda S, et al.: Neutralization profiles of primary human immunodeficiency virus type 1 isolates in the context of coreceptor usage. J Virol 1998;72:6988-6996.
21. Moore JP and Burton DR: HIV-1 neutralizing antibodies: How full is the bottle? Nat Med 1999;5:142-144.
22. Gray ES, Moore PL, Choge IA, Decker JM, Bibollet-Ruche F, Li H, et al.: Neutralizing antibody responses in acute human immunodeficiency virus type 1 subtype C infection. J Virol 2007;81:6187-6196.
23. Connick E, Marr DG, Zhang X, Clark SJ, Saag MS, Schooley RT, et al.: HIVspecific cellular and humoral immune responses in primary HIV infection. AIDS Res Hum Retroviruses 1996;12:1129-1140.
24. Bures R, Morris L, Williamson C, Ramjee G, Deers M, Fiscus SA, et al.: Regional clustering of shared neutralization determinants on primary isolates of clade C human immunodeficiency virus type 1 from South Africa. J Virol 2002;76:2233-2244.
25. Aasa-Chapman MMI, Hayman A, Newton P, Cornforth D, Williams I, Borrow P, et al.: Development of the antibody response in acute HIV-1 infection. AIDS 2004;18:371-381.
26. Nyambi PN, Mbah HA, Burda S, Williams C, Gorny MK, Nadas A, et al.: Conserved and exposed epitopes on intact and native human immunodeficiency virus type 1 virions of group M. J Virol 2000;749:7096-7107.
27. Spenlehauer C, Saragosti S, Sarasgosti S, Harvey HJA, Kirn A, Aubertin AM, et al.: Study of the V3 loop as a target epitope for antibodies involved in the neutralization of primary isolates versus T-cell line adapted strains of human immunodeficiency virus type 1. J Virol 1998;72:9855-9864.
28. Moore PL, Gray ES, Choge IA, Ranchobe N, Mlisana K, Abdool Karim SS, et al.: The C3-V4 region is a major target of autologous neutralizing antibodies in human immunodeficiency virus type 1 subtype C infection. J Virol 2008;82:1860-1869.
29. Emini EA, Schleif WA, Nunberg JH, Conley AJ, Eda Y, Tokiyoshi S, et al.: Prevention of HIV-1 infection in chimpanzees by gp120 V3 domain-specific monoclonal antibody. Nature 1992;20:355:728-730.
30. Gorny MK, Williams C, Volsky B, Revesz K, Cohen S, Polonis VR, et al.: Human monoclonal antibodies specific for conformation-sensitive epitopes of V3 neutralize HIV-1 primary isolates from various clades. J Virol 2004;76:9035-9045.
31. Lewis J, Balfe P, Arnold C, Kaye S, Tedder RS, and McKeating JA: Development of a neutralizing antibody response during acute primary human immunodeficiency virus type 1 infection and the emergence of antigenic variants. J Virol 1998;72:8943-8951.
32. Means RE, Matthews T, Hoxie JA, Malim MH, Kodama T, and Desrosiers RC: Ability of the V3 loop of simian immunodeficiency virus to serve as a target for antibody-mediated neutralization: Correlation of neutralization sensitivity, growth in macrophages, and decreased dependence on CD4. J Virol 2001;75:3903-3915.
33. Bou-Habib DC, Roderiquez G, Oravecz T, Berman PW, Lusso P, and Norcross MA: Cryptic nature of envelope V3 region epitopes protects primary monocytotropic human immunodeficiency virus type 1 from antibody neutralization. J Virol 1994;68:6006-6013.
34. Li B, Decker JM, Johnson RW, Bibollet-Ruche F, Wei X, Mulenga J, et al.: Evidence for potent autologous neutralizing antibody titers and compact envelopes in early infection with subtype C human immunodeficiency virus type 1. J Virol 2006;80:5211-5218.
35. Wyatt R, Moore JP, Accola M, Desjardin E, Robinson J, and Sodroski J: Involvement of the V1/V2 variable loop structure in the exposure of human immunodeficiency virus type 1 gp 120 epitopes induced by receptor binding. J Virol 1995;69:5723-5733.